Abstracts tagged "Fibroblasts, Other"

Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Kastriot Kastrati¹, Thomas S Nakuz², Oana C Kulterer², Stephan Blüml³, Michael Bonelli³, Irina Gessl⁴, Hans-Peter Kiener³, Werner Langsteger², Daniel Mrak³, Florian Prayer⁵, Helmut Prosch⁵, Elisabeth Simader³, Tatjana Traub-Weidinger², Daniel Aletaha⁶, Helga Radner⁷, Marcus Hacker² and Peter Mandl³, ¹Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
Abstract Number: 0934 • ACR Convergence 2023
Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis
Hiroshi Matsuura¹, Masahiro Kondo¹, Ryoko Ohno¹, Akina Ishii¹, Mariam Piruzyan¹, Kaori Funayama¹, Yuuichi Ono¹, Atsushi Iwamura¹, Tadashi Endo¹, Tomoya Akashi¹, Taizo Tomari², Noriko Uchiyama², Noriyasu Seki¹, Kenji Chiba¹, Gabriela Kania³, Przemyslaw Blyszczuk⁴, Oliver Distler⁵, Tsutomu Takeuchi⁶ and Yuko Kaneko⁷, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Japan, ³University of Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Targeted small-molecule therapies to autotaxin (ATX), the lysophosphatidic acid (LPA)-producing enzyme, have been shown to be potentially effective in systemic sclerosis (SSc), but the…
Abstract Number: 1596 • ACR Convergence 2023
A Cell and Transcriptomic Atlas of the Infrapatellar Fat Pad from Patients with Knee Osteoarthritis: Identification of an Obesity-Associated Transcriptomic Signature
Hayley Peters¹, Pratibha Potla¹, Jason Rockel¹, Keemo Delos Santos¹, Shabana Vohra¹, starlee lively², Kim Perry³, Anthony Perruccio¹, Nizar Mahomed⁴, Raja Rampersaud¹, Rajiv Gandhi⁵ and Mohit Kapoor⁶, ¹Schroeder Arthritis Institute, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁴Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Orthopaedics, Department of Surgery, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (KOA) is the most common form of arthritis that affects multiple knee joint tissues. The infrapatellar fat pad is the largest fat…
Abstract Number: 2357 • ACR Convergence 2023
The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Itzchak Amoyal¹, Tzipi Hornik-Lurie², Tali Zitman-Gal¹, Hilit Levy³, Ilan Vaknin³, Liat Drucker⁴, Ishai Heusler⁵, Yair Levy¹ and Shelly Tartakover Matalon¹, ¹Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ²Meir Medical Center, Data Research Department, Kfar-Saba, Israel, ³Chemomab Ltd, Tel Aviv, Israel, ⁴Meir Medical Center, Oncogenetics Laboratory, Kfar Saba, Israel, ⁵Meir Medical Center, Department of Obstetric and Genecology, Kfar-Saba, Israel
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs. Endothelial cells (ECs),…
Abstract Number: 1173 • ACR Convergence 2022
Single-cell Multi-omic Analysis of a 3D Skin-Like Tissue Model Provides Insights into Molecular and Cellular Drivers of Systemic Sclerosis
Tamar Abel¹, Noelle Kosarek², Rezvan Parvizi³, Helen Jarnagin¹, Mengqi Huang⁴, Avi Smith⁵, Michael Mariani¹, Dillon Popovich⁶, Heetaek Yang⁷, Tammara Wood⁸, Jonathan Garlick⁹, Patricia Pioli⁷ and Michael Whitfield¹⁰, ¹Dartmouth College, Lebanon, NH, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth, Lebanon, NH, ⁴University of Pittsburgh, Pittsburgh, PN, ⁵Tufts University, Boston, MA, ⁶Dartmouth College, West Lebanon, NH, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁸Dartmouth College, Hanover, NH, ⁹Tufts University School of Dental Medicine, Boston, MA, ¹⁰Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic Sclerosis (SSc) currently lacks reliable in vitro models of skin fibrosis constructed from all human cells. We have developed a skin-like tissue model of systemic…
Abstract Number: 1621 • ACR Convergence 2022
Genome-wide Association Study in African American Systemic Sclerosis Patients Identifies a Novel Target – Transforming Growth Factor-β3 (TGFβ3)
Urvashi Kaundal¹, Julia Hartman², Emilee Stenson¹, Sarah Safran¹, Chloe Borden¹, Mousumi Sahu¹, Janet Wang¹, Andrea Conte¹, Ami Shah³, Maureen Mayes⁴, Ayo Doumatey⁵, Amy Bentley⁵, Daniel Shriner⁵, Robyn Domsic⁶, Thomas Medsger⁷, Paula Ramos⁸, Richard Silver⁸, Virginia Steen⁹, John Varga¹⁰, Vivien Hsu¹¹, Lesley Ann Saketkoo¹², Elena Schiopu¹³, Dinesh Khanna¹⁴, Jessica Gordon¹⁵, Lindsey Criswell¹⁶, Heather Gladue¹⁷, Chris Derk¹⁸, Elana Bernstein¹⁹, S. Louis Bridges, Jr.¹⁵, Victoria Shanmugam²⁰, Lorinda Chung²¹, Suzanne Kafaja²², Reem Jan²³, Marcin Trojanowski²⁴, Avram Goldberg²⁵, Benjamin Korman²⁶, Settara Chandrasekharappa⁵, Yongbing Zhao²⁷, Stephen Brooks²⁷, Stefania Dell'Orso¹, Adebowale Adeyemo⁵, Charles Rotimi⁵, Elaine Remmers⁵, Daniel Kastner⁵, Francesco Boin²⁸, Rafael Casellas²⁷, Fredrick Wigley²⁹ and Pravitt Gourh³⁰, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rutgers-RWJ Medical School, South Plainfield, NJ, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Michigan Medicine, Ann Arbor, MI, ¹⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁷Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Columbia University, New York, NY, ²⁰George Washington University, Great Falls, VA, ²¹Stanford University, Stanford, CA, ²²UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²³University of Chicago, Chicago, IL, ²⁴Boston University School of Medicine, Boston, MA, ²⁵NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁶University of Rochester, Rochester, NY, ²⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²⁸Cedars-Sinai Medical Center, Los Angeles, CA, ²⁹Johns Hopkins University, Baltimore, MD, ³⁰National Institutes of Health, Bethesda, MD
Background/Purpose: Transforming Growth Factor-β (TGFβ) isoforms play an important role in extracellular matrix biology. Increased TGFβ-regulated gene signature has been observed in lesional skin and…
Abstract Number: 1623 • ACR Convergence 2022
Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis
Ievgeniia Kocherova¹, Elena Pachera², Daria Nurzynska³, Franca Di Meglio³, Oliver Distler⁴, Przemysław Błyszczuk² and Gabriela Kania², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Department of Public Health, University of Naples "Federico II", Naples, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of cardiac mortality in patients with systemic autoimmune diseases.…
Abstract Number: 0037 • ACR Convergence 2022
Dual (and Dueling) Fibroblast Differentiation Is Integral to the Pathogenesis of Anti-Ro Mediated Congenital Heart Block and Provides a Novel Biomarker of Severity
Christina Firl¹, Robert Clancy², Bettina Cuneo³, Nicola Fraser⁴, Marc Halushka⁵, Mala Masson⁶, Amit Saxena¹ and Jill Buyon², ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴NYU School of Medicine, New York, NY, ⁵Johns Hopkins Medicine, Baltimore, MD, ⁶NYU Langone Medical Center- Division of Rheumatology, New York, NY
Background/Purpose: Fibroblast heterogeneity may provide critical insights into autoimmune mediated tissue damage. Transdifferentiation to a scarring myofibroblast is characterized by expression of alpha-Smooth Muscle Actin…
Abstract Number: 0560 • ACR Convergence 2022
IL-17 Regulates Apolipoprotein E in Lymph Node Stromal Cells During Infection and Autoimmunity
Catherine Poholek¹ and Mandy McGeachy², ¹UPM Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoimmune disease (AID) resulting from a dysregulated immune response is associated with substantial morbidity and mortality, largely driven by cardiovascular disease (CVD)/atherosclerosis and dyslipidemia.…
Abstract Number: 0585 • ACR Convergence 2022
Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
Takeo Isozaki¹, Rei Takahashi², Kohei Maeda², Toshihiro Tanioka², Kunika Shimizu³, Kazutaka Kawamori³, Noriko Konishi⁴, Shinichiro Nishimi³, Sho Ishii³, Kuninobu Wakabayashi³ and Tsuyoshi Kasama³, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ³Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…
Abstract Number: 0516 • ACR Convergence 2021
Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block
Christina Firl¹, Miao Chang², Jill Buyon³ and Robert Clancy¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Linking inflammation to fibrosis, a common end stage feature of many autoantibody mediated rheumatic diseases, remains a challenge. Indeed the signature hallmark of anti-Ro…
Abstract Number: 1917 • ACR Convergence 2021
Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels
Timothy Wilson¹, Kevin Deane², Joyce Lee¹, Christopher Collora³, Marie Feser³, Mariana Kaplan⁴, Joshua Solomon⁵ and Kristen Demoruelle⁶, ¹University of Colorado, Denver, CO, ²University of Colorado Denver, Denver, CO, ³University of Colorado Denver, Aurora, CO, ⁴National Institutes of Health, Bethesda, MD, ⁵National Jewish Health, Denver, CO, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Increased levels of transforming growth factor β1 (TGF-β1) in the lung have been implicated in the pathogenesis of several fibrotic lung diseases, but their…
Abstract Number: 0395 • ACR Convergence 2020
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
Julia Hartman¹, Andrea Conte², Chloe Borden³, Urvashi Kaundal⁴, Yongbing Zhao², Sarah Safran⁵, Ami Shah⁶, Maureen Mayes⁷, Ayo Doumatey⁸, Amy Bentley⁹, Daniel Shriner⁸, Robyn Domsic¹⁰, Thomas Medsger¹¹, Paula Ramos¹², Richard Silver¹³, Virginia Steen¹⁴, John Varga¹⁵, Vivien Hsu¹⁶, Lesley Ann Saketkoo¹⁷, Elena Schiopu¹⁸, Dinesh Khanna¹⁹, Jessica Gordon²⁰, Lindsey Criswell²¹, Heather Gladue²², Chris Derk²³, Elana Bernstein²⁴, S. Louis Bridges²⁵, Victoria Shanmugam²⁶, Kathleen Kolstad²⁷, Lorinda Chung²⁸, Suzanne Kafaja²⁹, Reem Jan³⁰, Marcin Trojanowski³¹, Avram Goldberg³², Benjamin Korman³³, Monique Hinchcliff³⁴, Settara Chandrasekharappa⁸, Stefania Dell'Orso³, Adebowale Adeyemo⁸, Charles Rotimi⁸, Elaine Remmers³⁵, Fredrick Wigley³⁶, Daniel Kastner³⁵, Francesco Boin³⁷, Rafael Casellas² and Pravitt Gourh⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, ⁶Johns Hopkins University School of Medicine, Ellicott City, MD, ⁷University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁸National Human Genome Research Institute, Bethesda, ⁹National Human Genome Research Institute (NHGRI), NIH, Bethedsa, MD, ¹⁰University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹¹University of Pittsburgh School of Medicine, Verona, PA, ¹²Medical University of South Carolina, Charleston, SC, ¹³Medical University of South Carolina, Charleston, ¹⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁵Northwestern University, Chicago, IL, ¹⁶Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁷Scleroderma Patient Care and Research Center, Tulane University, New Orleans, LA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Hospital for Special Surgery, New York, NY, ²¹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ²²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Columbia University, New York, NY, ²⁵University of Alabama at Birmingham, Mountain Brk, AL, ²⁶The George Washington University, Washington, DC, ²⁷Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ²⁹David Geffen School of Medicine, UCLA, Los Angeles, CA, ³⁰Pritzker School of Medicine, University of Chicago, Chicago, IL, ³¹Boston University Medical Center, BOSTON, MA, ³²NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ³³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³⁴Yale School of Medicine, Westport, CT, ³⁵National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ³⁶Johns Hopkins University School of Medicine, Baltimore, MD, ³⁷University of California San Francisco, Cedars-Sinai, West Hollywood, CA
Background/Purpose: African American (AA) patients have a higher prevalence of SSc than European Americans (EA). Adding to this health disparity, AA SSc patients are more…
Abstract Number: 1256 • ACR Convergence 2020
Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
Shinjiro Kaieda¹, Kyoko Fujimoto¹ and Hiroaki Ida¹, ¹Kurume University School of Medicine, Kurume, Japan
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis in…
Abstract Number: 1911 • ACR Convergence 2020
IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1
Caya McFalls¹ and Carol Artlett¹, ¹Drexel University College of Medicine, Philadelphia
Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].